New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - olaparib 50mg - capsule - 50 mg - active: olaparib 50mg excipient: gellan gum hypromellose lauroyl macrogol-32 glycerides iron oxide black potassium acetate shellac titanium dioxide - lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed brca-mutated (germline or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) after platinum-based chemotherapy. prior treatment must have included at least 2 courses of platinum-based regimens.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - osimertinib mesilate 47.7mg equivalent to osimertinib 40mg;   - film coated tablet - 40 mg - active: osimertinib mesilate 47.7mg equivalent to osimertinib 40mg   excipient: hyprolose iron oxide black iron oxide red iron oxide yellow macrogol 3350 mannitol microcrystalline cellulose polyvinyl alcohol purified talc sodium stearyl fumarate titanium dioxide - tagrisso is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) mutations. tagrisso is indicated for the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive non-small cell lung cancer. tagrisso is indicated for the adjuvant treatment after tumour resection in adult patients with non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) mutations.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - osimertinib mesilate 95.4mg equivalent to osimertinib 80 mg;   - film coated tablet - 80 mg - active: osimertinib mesilate 95.4mg equivalent to osimertinib 80 mg   excipient: hyprolose iron oxide black iron oxide red iron oxide yellow macrogol 3350 mannitol microcrystalline cellulose polyvinyl alcohol purified talc sodium stearyl fumarate titanium dioxide - tagrisso is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) mutations. tagrisso is indicated for the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive non-small cell lung cancer. tagrisso is indicated for the adjuvant treatment after tumour resection in adult patients with non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) mutations.

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaccines - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older.the use of this vaccine should be in accordance with official recommendations.

India - English - Central Drugs Standard Control Organization

astrazeneca - cetrimide,chlorhexidine gluconate - strong7.5,1.5;% - 115ml/1lit.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - fentanyl citrate, quantity: 78.6 microgram/ml (equivalent: fentanyl, qty 50 microgram/ml) - injection, solution - excipient ingredients: sodium chloride; water for injections; citric acid; sodium citrate dihydrate; sodium hydroxide - indications as at 31 july 2003: short duration analgesia during pre-medication, induction and maintenance of anaesthesia, and in the immediate post operative period. opioid analgesic supplement to general and regional anaesthesia. combination with a neuroleptic as an anaesthetic pre medication for the induction of anaesthesia, and as an adjunct in the maintenance of general and regional anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - fentanyl citrate, quantity: 78.6 microgram/ml (equivalent: fentanyl, qty 50 microgram/ml) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride; sodium citrate dihydrate; citric acid - indications as at 31 july 2003: short duration analgesia during pre-medication, induction and maintenance of anaesthesia, and in the immediate post operative period. opioid analgesic supplement to general and regional anaesthesia. combination with a neuroleptic as an anaesthetic pre medication for the induction of anaesthesia, and as an adjunct in the maintenance of general and regional anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - potassium chloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - sodium chloride, quantity: 200 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - indications as at 19 february 1993 : as an additive to parenteral fluids in patients who have specific electrolyte needs. as a sclerosing agent for small symptomatic varicose veins.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - neostigmine methylsulfate -